{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034829","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.016731+00:00","generated_at":"2026-05-16T20:43:15.187942+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vaxart reports Q3 revenue $72.4M, net loss $8.1M; signs Dynavax COVID-19 pill license deal worth up to $700M","bullets":["Revenue $72.4M (vs $4.9M Q3 2024) from BARDA contract; net loss $8.1M ($0.04 EPS) vs $14.1M loss.","Exclusive license with Dynavax: $25M upfront + $5M equity; up to $700M in milestones and royalties.","Phase 2b COVID-19 trial enrollment completed (~5,400); topline data expected late 2026, sentinel cohort Q1 2026.","Cash, equivalents, investments $28.8M; with Dynavax payment runway extended to Q2 2027.","Phase 1 norovirus oral vaccine data shows robust fecal IgA; partnership discussions ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034829","json":"https://secwatch.observer/filing/0001437749-25-034829.json","markdown":"https://secwatch.observer/filing/0001437749-25-034829.md","text":"https://secwatch.observer/filing/0001437749-25-034829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925034829/0001437749-25-034829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925034829/vxrt20251112c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:43:15.187942+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}